Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
J Clin Lipidol ; 15(2): 311-319, 2021.
Article in English | MEDLINE | ID: mdl-33612457

ABSTRACT

BACKGROUND: Plasma lipoproteins contain heterogeneous subclasses. Previous studies on the associations of the complement system with lipids and lipoproteins are mainly limited to the major lipid classes, and associations of complement with lipoprotein subclass characteristics remain unknown. OBJECTIVE: We investigated the associations of C3 and other components of the alternative complement pathway with plasma lipoprotein subclass profile. METHODS: Plasma complement concentrations (complement component 3 [C3], properdin, factor H, factor D, MASP-3, C3a, Bb), and lipoprotein subclass profile (as measured by nuclear magnetic resonance spectroscopy) were obtained in 523 participants (59.6 ± 6.9 years, 60.8% men) of the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study. Multiple linear regression was used to investigate the associations of C3 (primary determinant) and other alternative pathway components (secondary determinants) with characteristics (particle concentration and size [main outcomes], and lipid contents [secondary outcomes]) of 14 lipoprotein subclasses, ranging from extremely large VLDL to small HDL (all standardized [std] values). RESULTS: Participants with higher C3 concentrations had more circulating VLDL (stdßs ranging from 0.27 to 0.36), IDL and LDL (stdßs ranging from 0.14 to 0.17), and small HDL (stdß = 0.21). In contrast, they had fewer very large and large HDL particles (stdßs = -0.36). In persons with higher C3 concentrations, all lipoprotein subclasses were enriched in triglycerides. Similar but weaker associations were observed for properdin, factor H, factor D, and MASP-3, but not for C3a and Bb. CONCLUSIONS: The alternative complement pathway, and most prominently C3, is associated with an adverse lipoprotein subclass profile that is characterized by more triglyceride-enriched lipoproteins but fewer large HDL.


Subject(s)
Lipoproteins , Triglycerides , Cohort Studies , Diabetes Mellitus , Humans , Middle Aged
2.
Diabetologia ; 63(5): 1032-1042, 2020 05.
Article in English | MEDLINE | ID: mdl-31993713

ABSTRACT

AIMS/HYPOTHESIS: Reactive α-dicarbonyl compounds are major precursors of AGEs and may lead to glycation of circulating and/or cell-associated complement regulators. Glycation of complement regulatory proteins can influence their capacity to inhibit complement activation. We investigated, in a human cohort, whether greater dicarbonyl stress was associated with more complement activation. METHODS: Circulating concentrations of dicarbonyl stress markers, i.e. α-dicarbonyls (methylglyoxal [MGO], glyoxal [GO] and 3-deoxyglucosone [3-DG]), and free AGEs (Nε-(carboxymethyl)lysine [CML], Nε-(carboxyethyl)lysine [CEL] and Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine [MG-H1]), and protein-bound AGEs (CML, CEL, pentosidine), as well as the complement activation products C3a and soluble C5b-9 (sC5b-9), were measured in 530 participants (59.5 ± 7.0 years [mean ± SD], 61% men) of the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study. Multiple linear regression analyses were used to investigate the associations between dicarbonyl stress (standardised) and complement activation (standardised) with adjustment of potential confounders, including age, sex, lifestyle, use of medication and markers of obesity. In addition, the associations of two potentially functional polymorphisms (rs1049346, rs2736654) in the gene encoding glyoxalase 1 (GLO1), the rate-limiting detoxifying enzyme for MGO, with C3a and sC5b-9 (all standardized) were evaluated. RESULTS: After adjustment for potential confounders, plasma concentration of the dicarbonyl GO was inversely associated with sC5b-9 (ß -0.12 [95% CI -0.21, -0.02]) and the protein-bound AGE CEL was inversely associated with C3a (-0.17 [-0.25, -0.08]). In contrast, the protein-bound AGE pentosidine was positively associated with sC5b-9 (0.15 [0.05, 0.24]). No associations were observed for other α-dicarbonyls and other free or protein-bound AGEs with C3a or sC5b-9. Individuals with the AG and AA genotype of rs1049346 had, on average, 0.32 and 0.40 SD lower plasma concentrations of sC5b-9 than those with the GG genotype, while concentrations of C3a did not differ significantly between rs1049346 genotypes. GLO1 rs2736654 was not associated with either C3a or sC5b-9. CONCLUSIONS/INTERPRETATION: Plasma concentrations of dicarbonyl stress markers showed distinct associations with complement activation products: some of them were inversely associated with either C3a or sC5b-9, while protein-bound pentosidine was consistently and positively associated with sC5b-9. This suggests different biological relationships of individual dicarbonyl stress markers with complement activation.


Subject(s)
Complement Activation/physiology , Diabetes Mellitus/metabolism , Diabetes Mellitus/physiopathology , Aged , Cohort Studies , Complement Activation/genetics , Diabetes Mellitus/genetics , Female , Genotype , Glycation End Products, Advanced/metabolism , Humans , Lactoylglutathione Lyase/genetics , Lactoylglutathione Lyase/metabolism , Male , Middle Aged , Pyruvaldehyde/metabolism
3.
Endocrine ; 62(3): 617-627, 2018 12.
Article in English | MEDLINE | ID: mdl-30132263

ABSTRACT

PURPOSE: We investigated the associations of components of the alternative (C3, C3a, Bb, factor D [FD], factor H [FH], properdin) and the classical complement pathway (C4, C1q, C1-inhibitor [C1-INH]) with prevalent and incident metabolic syndrome in a cohort with a moderately increased risk of cardiometabolic disease. METHODS: The study cohort was comprised of 574 participants (61% men, age 59.6 ± 7.0 years) at baseline and 489 participants after 7-year follow-up. Multiple logistic regression analyses were done to investigate the associations of concentrations of baseline plasma complement (standardized values) with prevalent and incident (in those without metabolic syndrome at baseline, n = 189) metabolic syndrome. RESULTS: C3 (odds ratio (OR) = 1.48 [95% confidence interval: 1.02; 2.14]) and C4 (OR = 1.95 [1.32; 2.88]), but none of the other complement components were associated with incident metabolic syndrome (n = 40 cases). Notably, in the cross-sectional analyses, we did observe higher levels of C3a (OR = 1.25 [1.03; 1.52]), FH (OR = 2.93 [2.24; 3.83]), and properdin (OR = 1.88 [1.50; 2.34]), in addition to C3 (OR = 3.60 [2.73; 4.75]) and C4 (OR = 1.39 [1.13; 1.69]), in those with the metabolic syndrome compared to those without, while no association was observed for FD, Bb, C1q, or C1-INH. CONCLUSIONS: In the cross-sectional analyses, the effects sizes (standardized regression coefficients) for C3 and C4 were similar to those of (some of) the regulators and activators, yet only C3 and C4 were associated with incident disease. These findings suggest a role for C3 and C4, but not their regulators or activated products, in the development of the metabolic syndrome.


Subject(s)
Complement C3/metabolism , Complement C4/metabolism , Metabolic Syndrome/blood , Aged , Complement Factor D/metabolism , Complement Factor H/metabolism , Cross-Sectional Studies , Female , Health Surveys , Humans , Incidence , Male , Metabolic Syndrome/epidemiology , Middle Aged , Prevalence
4.
Arterioscler Thromb Vasc Biol ; 38(5): 1242-1244, 2018 05.
Article in English | MEDLINE | ID: mdl-29567681

ABSTRACT

OBJECTIVE: The classical complement pathway has been assigned both protective and pathological effects in cardiovascular disease (CVD), but human data are lacking. We determined the associations of the pattern recognition factor C1q and the regulator C1-INH (C1-inhibitor) with incident CVD, carotid intima-media thickness, endothelial dysfunction, and low-grade inflammation. APPROACH AND RESULTS: Baseline concentrations of C1q and C1-INH were measured in the CODAM study (Cohort on Diabetes and Atherosclerosis Maastricht; n=574; 61% men; age, 60±7 years). The 7-year incidence of CVD in participants free of CVD at baseline was evaluated using logistic regression analyses (n=342; 73 cases). The lowest incidence of CVD was observed in the middle tertile of C1q (Tlow compared with Tmiddle: odds ratio, 2.38 [95% confidence interval, 1.14-4.95]; Thigh compared with Tmiddle: odds ratio, 1.96 [95% confidence interval, 0.94-4.07]). C1-INH was not associated with CVD. During the 7-year follow-up period, C1q and C1-INH were not, or inconsistently, associated with carotid intima-media thickness or with biomarker scores reflecting endothelial dysfunction and low-grade inflammation. CONCLUSIONS: Our results suggest a nonlinear association between C1q and incident CVD. This supports the concept that early steps in classical pathway activation may have both protective and pathological effects on human CVD.


Subject(s)
Cardiovascular Diseases/immunology , Complement C1 Inhibitor Protein/immunology , Complement C1q/immunology , Complement Pathway, Classical , Adult , Aged , Biomarkers/blood , Cardiovascular Diseases/diagnostic imaging , Cardiovascular Diseases/epidemiology , Carotid Intima-Media Thickness , Cell Adhesion Molecules/blood , Complement C1 Inhibitor Protein/metabolism , Complement C1q/metabolism , Female , Humans , Incidence , Inflammation Mediators/blood , Longitudinal Studies , Male , Middle Aged , Netherlands/epidemiology , Prognosis , Prospective Studies , Risk Assessment , Risk Factors , Time Factors
5.
Obes Res Clin Pract ; 12(3): 286-292, 2018.
Article in English | MEDLINE | ID: mdl-29174517

ABSTRACT

OBJECTIVE: To investigate longitudinal associations of components of the alternative (C3, C3a, Bb, factor D [FD], factor H [FH], and properdin) and the terminal complement pathway (C5a, sC5b-9) with adiposity. METHODS: A prospective human cohort study (n=574 at baseline, n=489 after 7 years follow-up) was analyzed. Generalized estimating equations were used to evaluate the longitudinal associations between complement components (standardized values) and adiposity (main outcome BMI [kg/m2]). Multiple linear regression models were used to investigate the associations between change in complement levels and change in BMI. Analyses were adjusted for age, sex, medication and lifestyle. RESULTS: Over the 7-year period, baseline C3 was positively associated with BMI (ß=1.72 [95% confidence interval (CI): 1.35; 2.09]). Positive associations were also observed for C3a (ß=0.64 [0.31; 0.97]), FD (ß=1.00 [0.59; 1.42]), FH (ß=1.17 [0.82; 1.53]), and properdin (ß=0.60 [0.28; 0.92]), but not for Bb, C5a or sC5b-9. Moreover, changes in C3 (ß=0.52 [0.34; 0.71]) and FH (ß=0.51 [0.32; 0.70]) were significantly associated with changes in BMI. CONCLUSIONS: The complement system, particularly activation of the alternative pathway, may be involved in development of adiposity. Whether individual aspects of alternative pathway activation have a causal role in human obesity, remains to be investigated.


Subject(s)
Adiposity/immunology , Adiposity/physiology , Complement Activation/physiology , Complement Pathway, Alternative/physiology , Aged , Biomarkers/metabolism , Complement System Proteins/metabolism , Female , Follow-Up Studies , Humans , Inflammation/physiopathology , Longitudinal Studies , Male , Middle Aged , Prospective Studies
6.
Arterioscler Thromb Vasc Biol ; 36(6): 1278-85, 2016 06.
Article in English | MEDLINE | ID: mdl-27055907

ABSTRACT

OBJECTIVE: Previous studies suggested that the lectin-complement pathway plays a complex role in cardiovascular disease (CVD). To date, no prospective human studies have investigated the relationship between the initiating factor of the lectin pathway, that is, mannose-binding lectin (MBL), and low-grade inflammation, endothelial dysfunction, or carotid intima-media thickness (cIMT). Moreover, MBL-associated proteases (MASPs) and MBL-associated proteins (MAps), which mediate downstream complement activation, have not been studied in the development of CVD. APPROACH AND RESULTS: In a prospective cohort (n=574; age 60±7 years; 7-year follow-up), we investigated longitudinal associations of plasma MBL, MASP-1, MASP-2, MASP-3, and MAp44 with biomarker scores that reflect low-grade inflammation and endothelial dysfunction, respectively, and with cIMT. We also investigated their associations with incident CVD (n=73). In adjusted analyses, low-grade inflammation was lowest in the middle tertile (TMiddle) of MBL, that is, TMiddle was 0.19 SD (0.03 to 0.34) lower than TLow, and 0.15 SD (-0.02 to 0.31) lower than THigh. cIMT was 28 µm (-50 to -5) lower in the highest MBL tertile (THigh) than in TMiddle and did not differ between TLow and TMiddle. MBL was not associated with endothelial dysfunction or CVD. MASP-1 and MASP-2 were not associated with any cardiovascular outcomes. MASP-3 and MAp44 were, independently of MBL levels, associated with endothelial dysfunction (per 1 SD higher MASP-3: ß=0.10 SD [0.02 to 0.18]; per 1 SD higher MAp44 ß=0.12 SD [0.04 to 0.20]) but not with low-grade inflammation, cIMT, or CVD. CONCLUSIONS: High MBL may contribute to low cIMT, whereas the association of MBL with low-grade inflammation was nonlinear. MASP-1 and MASP-2 were not associated with adverse cardiovascular outcomes. MASP-3 and MAp44 may play a role in endothelial dysfunction, potentially independent of lectin-pathway activation.


Subject(s)
Carotid Arteries/diagnostic imaging , Carotid Artery Diseases/blood , Carotid Intima-Media Thickness , Diabetes Mellitus/blood , Endothelium, Vascular/physiopathology , Inflammation/blood , Mannose-Binding Lectin/blood , Mannose-Binding Protein-Associated Serine Proteases/analysis , Aged , Biomarkers/blood , Carotid Arteries/physiopathology , Carotid Artery Diseases/diagnostic imaging , Carotid Artery Diseases/epidemiology , Carotid Artery Diseases/physiopathology , Diabetes Mellitus/diagnosis , Diabetes Mellitus/epidemiology , Female , Genotype , Humans , Incidence , Inflammation/diagnosis , Inflammation/epidemiology , Logistic Models , Longitudinal Studies , Male , Mannose-Binding Lectin/genetics , Middle Aged , Netherlands/epidemiology , Nonlinear Dynamics , Predictive Value of Tests , Prognosis , Prospective Studies , Risk Assessment , Risk Factors , Time Factors
7.
Thromb Haemost ; 115(2): 446-57, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26446431

ABSTRACT

The alternative pathway of complement activation is highly reactive and can be activated spontaneously in the vasculature. Activation may contribute to vascular damage and development of cardiovascular disease (CVD). We aimed to investigate functional components of the alternative pathway in cardiovascular risk. We studied 573 individuals who were followed-up for seven years. At baseline, we measured the enhancer properdin; the rate-limiting protease factor D (FD); and a marker of systemic activation, Bb. Using generalised estimating equations, we investigated their longitudinal associations with cardiovascular events (CVE, N=89), CVD (N=159), low-grade inflammation (LGI), endothelial dysfunction (ED) and carotid intima-media thickness (cIMT). Furthermore, we investigated associations with incident CVE (N=39) and CVD (N=73) in 342 participants free of CVD at baseline. CVE included myocardial infarction, stroke, cardiac angioplasty and/or cardiac bypass. CVD additionally included ischaemia on an electrocardiogram and/or ankle-brachial index < 0.9. In adjusted analyses, properdin was positively associated with CVE (per 1SD, longitudinal OR=1.36 [1.07; 1.74], OR for incident CVE=1.53 [1.06; 2.20]), but not with CVD. Properdin was also positively associated with ED (ß=0.13 [95%CI 0.06; 0.20]), but not with LGI or cIMT. FD and Bb were positively associated with LGI (per 1SD, FD: ß=0.21 [0.12; 0.29], Bb: ß=0.14 [0.07; 0.21]), and ED (FD: ß=0.20 [0.11; 0.29], Bb: ß=0.10 [0.03; 0.18]), but not with cIMT, CVE or CVD. Taken together, this suggests that the alternative complement pathway contributes to processes of vascular damage, and that in particular a high potential to enhance alternative pathway activation may promote unfavourable cardiovascular outcomes in humans.


Subject(s)
Cardiovascular Diseases/blood , Complement Pathway, Alternative , Adult , Aged , Ankle Brachial Index , Biomarkers/metabolism , Cardiovascular Diseases/metabolism , Cardiovascular System , Carotid Intima-Media Thickness , Complement Activation , Complement C3/metabolism , Complement Factor D/metabolism , Electrocardiography , Female , Follow-Up Studies , Humans , Incidence , Inflammation , Longitudinal Studies , Male , Middle Aged , Myocardial Infarction/blood , Risk Factors , Stroke/blood
8.
Thromb Haemost ; 111(6): 1102-11, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24500020

ABSTRACT

Complement C3 is a novel risk factor for cardiovascular disease (CVD), but the underlying mechanism is currently unknown. We determined the associations of the anaphylatoxin C3a, the activation product of C3, and of C3 itself with estimates of atherosclerosis and CVD. We studied associations of C3a and C3 with carotid intima-media thickness (cIMT), ankle-arm blood pressure index (AAIx) and CVD in cross-sectional analyses among 545 participants of the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study (62% men, 59.4 ± 6.9 years) and examined effect modification by smoking. We conducted linear and logistic regression analyses with adjustments for age, sex, glucose metabolism status, lipids, adiposity, renal function, blood pressure, pack-years smoked, physical activity, use of medication and investigated mediation by inflammation. C3a was independently associated with cIMT (ß=0.032 mm, [95% confidence interval: 0.004; 0.060]) and AAIx (ß=-0.022, [-0.043; -0.001]), but C3 was not. Effect modification by smoking was only observed for CVD (P(smoking*C3a)=0.008, P(smoking*C3)=0.018), therefore these associations were stratified for smoking behaviour. Both C3a (odds ratio [OR] =2.96, [1.15; 7.62]) and C3 (OR =1.98, [1.21; 3.22]) were independently associated with CVD in heavy smokers. The association of C3 with CVD was independent of C3a. Low-grade inflammation did partially explain the association of C3a with AAIx, but not the other observed associations. This suggests that C3a and C3 have distinct roles in pathways leading to CVD. C3a may promote atherosclerosis and additionally advance CVD in heavy smokers. Conversely, C3 may be associated with CVD in heavy smokers via pathways other than atherosclerosis.


Subject(s)
Atherosclerosis/blood , Cardiovascular Diseases/blood , Complement C3/metabolism , Complement C3a/metabolism , Aged , Ankle , Arm , Atherosclerosis/etiology , Atherosclerosis/physiopathology , Blood Pressure , Cardiovascular Diseases/etiology , Cardiovascular Diseases/physiopathology , Carotid Intima-Media Thickness , Cohort Studies , Cross-Sectional Studies , Female , Humans , Inflammation Mediators/blood , Linear Models , Logistic Models , Male , Middle Aged , Risk Factors , Smoking/adverse effects
9.
Am J Physiol Endocrinol Metab ; 302(1): E52-60, 2012 Jan 01.
Article in English | MEDLINE | ID: mdl-21917635

ABSTRACT

The loss of skeletal muscle mass with aging has been attributed to an impaired muscle protein synthetic response to food intake. Therefore, nutritional strategies are targeted to modulate postprandial muscle protein accretion in the elderly. The purpose of this study was to assess the impact of protein administration during sleep on in vivo protein digestion and absorption kinetics and subsequent muscle protein synthesis rates in elderly men. Sixteen healthy elderly men were randomly assigned to an experiment during which they were administered a single bolus of intrinsically l-[1-(13)C]phenylalanine-labeled casein protein (PRO) or a placebo (PLA) during sleep. Continuous infusions with l-[ring-(2)H(5)]phenylalanine and l-[ring-(2)H(2)]tyrosine were applied to assess in vivo dietary protein digestion and absorption kinetics and subsequent muscle protein synthesis rates during sleep. We found that exogenous phenylalanine appearance rates increased following protein administration. The latter stimulated protein synthesis, resulting in a more positive overnight whole body protein balance (0.30 ± 0.1 vs. 11.8 ± 1.0 µmol phenylalanine·kg(-1)·h(-1) in PLA and PRO, respectively; P < 0.05). In agreement, overnight muscle protein fractional synthesis rates were much greater in the PRO experiment (0.045 ± 0.002 vs. 0.029 ± 0.002%/h, respectively; P < 0.05) and showed abundant incorporation of the amino acids ingested via the intrinsically labeled protein (0.058 ± 0.006%/h). This is the first study to show that dietary protein administration during sleep is followed by normal digestion and absorption kinetics, thereby stimulating overnight muscle protein synthesis. Dietary protein administration during sleep stimulates muscle protein synthesis and improves overnight whole body protein balance. These findings may provide a basis for novel interventional strategies to attenuate muscle mass loss.


Subject(s)
Aging/metabolism , Dietary Proteins/administration & dosage , Muscle Proteins/biosynthesis , Quadriceps Muscle/metabolism , Sleep , Aged , Aging/blood , Algorithms , Amino Acids/blood , Carbon Isotopes , Deuterium , Dietary Proteins/metabolism , Dietary Proteins/therapeutic use , Digestion , Enteral Nutrition , Humans , Hunger , Intestinal Absorption , Intubation, Gastrointestinal , Kinetics , Male , Sarcopenia/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...